Creatine as a Candidate to Prevent Statin Myopathy

Area of Science:

• Biochemistry
• Pharmacology
• Mitochondrial Biology

Background:

• Statins are widely prescribed for cardiovascular disease prevention.
• Statin-induced myopathy is a common dose-limiting side effect, often due to direct muscle toxicity.
• Statin-induced creatine deficiency is a proposed mechanism for muscle toxicity.

Purpose of the Study:

• To investigate the role of creatine deficiency in statin-induced myopathy.
• To evaluate the potential of creatine supplementation as a preventative or therapeutic strategy for statin myopathy.

Main Methods:

• In vitro studies on statin-treated cells to assess mitochondrial function and ATP synthesis.
• Examination of the effect of creatine supplementation on mitochondrial permeability transition pore opening.
• Clinical observation of statin-intolerant patients receiving creatine supplementation.

Main Results:

• Statins inhibit guanidinoacetate methyl transferase (GAMT), leading to decreased intracellular creatine levels.
• Reduced creatine impairs mitochondrial oxidative phosphorylation and ATP synthesis.
• Creatine supplementation prevented statin-induced mitochondrial dysfunction in vitro and myopathy in patients.

Conclusions:

• Statin-induced creatine deficiency is a likely cause of muscle toxicity.
• Creatine supplementation is a safe and potentially effective strategy to prevent or treat statin myopathy.
• Further clinical trials are warranted to confirm these findings and guide medical use.